LAG3 and melanoma: Preliminary data from a phase 1/2 study in melanoma patients showed the combination of nivolumab with BMS-986016 (IgG4 antibody targeting LAG3) had similar safety profile to nivolumab monotherapy, with encouraging efficacy [97].